Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406644 | 0.92 | NPC1 (0.39) | MDM2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5432422 | 0.91 | GRM2 (0.40) | KCNH2MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5397690 | 0.89 | MDM2 (0.40) | MDM2NPC1RAB9ASMN1; SMN2BCHE | |
| SCHEMBL4347443 | 0.88 | NPC1 (0.38) | MDM2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4347449 | 0.88 | NPC1 (0.38) | MDM2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5433709 | 0.88 | KCNH2 (0.42) | KCNH2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5434436 | 0.88 | NPC1 (0.37) | MDM2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5450497 | 0.87 | KCNH2 (0.42) | KCNH2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5399601 | 0.86 | CXCR1 (0.39) | KCNH2MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5428088 | 0.85 | KDR (0.38) | KCNH2MDM2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007523181-A | — | — | 2007-08-16 | — | — | JP | claimed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | claimed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | claimed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | claimed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | KCNH2 359/4885MDM2 4268/4885NPC1 2424/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | KCNH2 363/4885MDM2 4376/4885NPC1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.